A 2010 update on occult hepatitis B infection;Actualités en 2010 sur l'hépatite B occulte

Pathologie Biologie

Volumn 58, Issue 4, 2010, Pages 254-257

  Raimondo, G ^a   Pollicino, T ^a   Romano L ^b   Zanetti, A R ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti HBc; HBV; HBV DNA; Hepatitis B; OBI; Occult HBV infection

Indexed keywords

CIRCULAR DNA; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ARTICLE; BLOOD ANALYSIS; BLOOD TRANSFUSION; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; DNA DETERMINATION; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; LIVER CELL CARCINOMA; LIVER INJURY; LIVER PARENCHYMA; LIVER TRANSPLANTATION; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS REPLICATION; VIRUS TRANSMISSION;

BLOOD TRANSFUSION; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; ORGAN TRANSPLANTATION; SEROLOGIC TESTS;

EID: 77955392200     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.02.003     Document Type: Article

References (43)

1. Wands J.R., Chura C.M., Roll F.J., Maddrey W.C. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975, 68:105-112.
2. Hoofnagle J.H., Seeff L.D., Bales Z.B., Zimmerman H.J. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. New Engl J Med 1978, 298:1379-1383.
3. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
4. Raimondo G., Pollicino T., Cacciola I., Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007, 46:160-170.
5. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009, 51:581-592.
6. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infect Dis 2002, 2:479-486.
7. Michalak T.I., Mulrooney P.M., Coffin C.S. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 2004, 78:1730-1738.
8. Zerbini A., Pilli M., Boni C., Fisicaro P., Penna A., Di Vincenzo P., et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008, 134:1470-1481.
9. Shetty K., Hussain M., Nei L., Reddy K.R., Lok A.S. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008, 14:534-540.
10. Raimondo G., Navarra G., Mondello S., Costantino L., Colloredo G., Cucinotta E., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008, 48:743-746.
11. Hollinger F.B. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008, 48:1001-1026.
12. Allain J.P., Belkhiri D., Vermeulen M., Crookes R., Cable R., Amiri A., et al. Characterization of occult hepatitis B virus strains in South Africa blood donors. Hepatology 2009, 49:1868-1876.
13. Candotti D., Grabarczyk P., Ghiazza P., Roig R., Casamitjana N., Iudicone P., et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008, 49:537-547.
14. Brojer E., Grabarczyk P., Liszewski G., Mikulsulska M., Allain J.P., Letowska M. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006, 44:1666-1674.
15. Velati C., Romanò L., Fomiatti L., Baruffi L. Zanetti AR and the SIMTI Research Group. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008, 48:2205-2213.
16. Satake M., Taira R., Yugi H., Satory H., Kanemitsu K., Ikeda H., et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007, 47:1197-1205.
17. Hollinger F.B., Dressman G.R., Fields H., Melnick J. HBcAg, anti-HBc, and DNA polymerase activity in transfused recipients followed prospectively. Am J Med Sci 1975, 270:343-348.
18. Aach R.D., Alter H.J., Hollinger F.B., Holland P.V., Lander J.J., Melnick J.L., et al. Risk of transfusion blood containing antibody to hepatitis B surface antigen. Lancet 1974, 2:190-193.
19. Allain J.P., Reesink H.W., Lucey C. A European perspective on the management of donors and units testing positive for hepatitis B virus DNA. Transfusion 2006, 46:1256-1258.
20. Prince A.M., Lee D.H., Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs positive cases of resolved hepatitis B infection. Transfusion 2001, 41:329-332.
21. Mosley J.W., Stevens C.E., Aach R.D., Hollinger F.B., Mimms L.T., Solomon L.R., et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995, 35:5-12.
22. Gerlich W.H., Wagner F.F., Chudy M., Harritshoj L.H., Lattermann A., Wienzek S., et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 2007, 79:S32-S36.
23. Candotti D., Allain J.P. Transfusion-transmitted hepatitis B infection. J Hepatol 2009, 51:798-809.
24. Chazouilleres O., Mamish D., Kim M., Carey K., Ferrell L., Roberts J.P., et al. Occult hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994, 343:142-146.
25. Dickson R.C., Everhart J.E., Lake J.R., Wei Y., Seaberg E.C., Wiesner R.H., et al. Trasmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997, 113:1668-1674.
26. Munoz S.J. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002, 8:S82-S87.
27. Roche B., Samuel D., Gigou M., Feray C., Virot V., Schmets L., et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997, 26:517-526.
28. Prieto M., Gomez M.D., Berenguer M., Cordoba J., Rayon J.M., Pastor M., et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7:51-58.
29. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis. J Hepatol 2006, 45:127-143.
30. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
31. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007, 136:699-712.
32. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M.E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. New Engl J Med 1999, 341:22-26.
33. Chemin I., Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005, 34:S15-21.
34. Chen Y.C., Sheen I.S., Chu C.M., Liaw Y.F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
35. Brechot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult" ?. Hepatology 2001, 34:194-203.
36. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004, 127:S56-61.
37. Chemin I., Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009, 286:52-59.
38. Shafritz D.A., Shouval D., Sherman H.I., Hadziyannis S.J., Kew M.C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. New Engl J Med 1981, 305:1067-1073.
39. Brechot C., Hadchouel M., Scotto J., Fonck M., Potet F., Vyas G.N., et al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A 1981, 78:3906-3910.
40. Marion P.I. In Ground squirrel hepatitis virus. Molecular biology of hepatitis B virus 1991, 39-51. CRC Press, Boca Raton, Florida. A. McLachlan (Ed.).
41. Korba B.E., Wells F.V., Baldwin B., Cote P.J., Tennant B.C., Popper H., et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989, 9:461-470.
42. Donato F., Gelatti U., Limina R.M., Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006, 25:3756-3770.
43. Pollicino T., Squadrito G., Cerenzia G., Cacciola I., Raffa G., Craxì A., et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004, 126:102-110.